GTE-001 / Grit Biotechnology - LARVOL DELTA

Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma (clinicaltrials.gov) - P1 | N=2 | Terminated | Sponsor: Grit Biotechnology | N=12 ➔ 2 | Recruiting ➔ Terminated; The study was terminated from a business perspective.

Enrollment change • Trial termination • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Grit Biotechnology | Trial completion date: Jul 2024 ➔ Jul 2027 | Trial primary completion date: Jul 2024 ➔ Jul 2027

Metastases • Trial completion date • Trial primary completion date • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Grit Biotechnology

Metastases • New P1 trial • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor